Patents Assigned to HEALIOS K.K.
-
Publication number: 20230287342Abstract: The invention provides a method for producing a retinal pigment epithelial cell by (1) maintaining and/or expanding human pluripotent stem cells comprising culturing the human pluripotent stem cells in the absence of a feeder cell in a medium comprising a factor for maintaining an undifferentiated state, (2) a first step for culturing the maintained and/or expanded human pluripotent stem cells in a medium comprising a MEK inhibitor in the absence of feeder cells for a period of not less than 2 days and not more than 30 days, wherein the culture condition in the first step is a condition sufficient for inducing gene expression of at least one eye field transcription factor, and (3) a second step for culturing the cells obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.Type: ApplicationFiled: April 4, 2023Publication date: September 14, 2023Applicants: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.Inventors: Satoshi ANDO, Takao KURODA
-
Patent number: 11752069Abstract: A cellular medicine transfer system includes: an adapter for a cellular medicine container including a first flow channel and a second flow channel through each of which a liquid and cells can flow; a cellular medicine container to which the adapter is attached, and in which a cellular medicine to be transferred is stored; an administration medium storage container that communicates with the first flow channel, and in which an administration medium is stored; a collection container for collecting a cellular medicine, that communicates with the second flow channel of the adapter; and a powering device that imparts motive power for transferring the administration medium from the administration medium storage container through the first flow channel to the cellular medicine container, and for transferring the cellular medicine and the administration medium from the cellular medicine container through the second flow channel to the collection container.Type: GrantFiled: November 27, 2018Date of Patent: September 12, 2023Assignees: HEALIOS K. K., SUMITOMO PHARMA CO., LTD.Inventors: Masakazu Inamori, Dai Otagiri
-
Publication number: 20230203445Abstract: The present invention provides a highly functional hypoimmunogenic cell, namely, a hypoimmunogenic human cell (1) lacking an endogenous gene encoding an ? chain of human leukocyte antigen (HLA) class Ia, (2) lacking an endogenous gene encoding HLA class II or an expression regulator thereof, (3) containing an exogenous gene encoding an ? chain of HLA class Ib, (4) containing an exogenous gene encoding human PD-L1, and (5) containing an exogenous gene encoding human PD-L2.Type: ApplicationFiled: May 26, 2021Publication date: June 29, 2023Applicant: HEALIOS K.K.Inventors: Kouichi TAMURA, Hironobu KIMURA, Tomonori HOSOYA, Norihiro TSUNEYOSHI
-
Patent number: 11649432Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps: (1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.Type: GrantFiled: September 8, 2016Date of Patent: May 16, 2023Assignees: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.Inventors: Satoshi Ando, Takao Kuroda
-
Patent number: 11618883Abstract: The present invention provides a production method of a retinal pigment epithelial cell containing the following steps: (1) a first step for culturing a pluripotent stem cell in a medium containing at least one kind selected from the group consisting of an FGF receptor inhibitor and an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in a medium containing at least one kind selected from the group consisting of a Rho signal transduction pathway inhibitor and an apoptosis inhibitor to form a retinal pigment epithelial cell. The method can produce retinal pigment epithelial cells from pluripotent stem cells more efficiently and conveniently.Type: GrantFiled: March 8, 2018Date of Patent: April 4, 2023Assignees: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.Inventor: Takao Kuroda
-
Patent number: 11524035Abstract: The present invention, in which RPE cells are suspended in a medium pharmaceutically acceptable as an ocular irrigating/washing solution and containing a poloxamer, achieves improvement of the post-thawing survival rate of cryopreserved RPE cells, improvement of the photoreceptor cell protection effect by RPE cell transplanted immediately after thawing, and prevention of loss of RPE cells in various steps from thawing to transplantation.Type: GrantFiled: June 29, 2017Date of Patent: December 13, 2022Assignees: HEALIOS K.K., SUMITOMO PHARMA CO., LTD.Inventors: Dai Otagiri, Tadao Maeda
-
Patent number: 11492593Abstract: The present invention provides a method of purifying highly pure retinal pigment epithelial cells from a cell population obtained by induction of differentiation of pluripotent stem cells into retinal pigment epithelial cells, by a simple and easy operation in a short period. The purification method of the present invention includes a step of introducing a cell population containing retinal pigment epithelial cells obtained by differentiation induction of pluripotent stem cells on laminin or a fragment thereof on a filter, and obtaining a cell population that passed the filter.Type: GrantFiled: October 9, 2014Date of Patent: November 8, 2022Assignees: HEALIOS K.K., OSAKA UNIVERSITYInventors: Masanori Sawada, Kiyotoshi Sekiguchi
-
Publication number: 20200009196Abstract: The present invention, in which RPE cells are suspended in a medium pharmaceutically acceptable as an ocular irrigating/washing solution and containing a poloxamer, achieves improvement of the post-thawing survival rate of cryopreserved RPE cells, improvement of the photoreceptor cell protection effect by RPE cell transplanted immediately after thawing, and prevention of loss of RPE cells in various steps from thawing to transplantation.Type: ApplicationFiled: June 29, 2017Publication date: January 9, 2020Applicants: HEALIOS K.K., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Dai OTAGIRI, Tadao MAEDA
-
Publication number: 20200010801Abstract: The present invention provides a production method of a retinal pigment epithelial cell containing the following steps: (1) a first step for culturing a pluripotent stem cell in a medium containing at least one kind selected from the group consisting of an FGF receptor inhibitor and an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in a medium containing at least one kind selected from the group consisting of a Rho signal transduction pathway inhibitor and an apoptosis inhibitor to form a retinal pigment epithelial cell. The method can produce retinal pigment epithelial cells from pluripotent stem cells more efficiently and conveniently.Type: ApplicationFiled: March 8, 2018Publication date: January 9, 2020Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., HEALIOS K.K.Inventor: Takao KURODA
-
Patent number: 10240201Abstract: The present invention provides an agent for treating ophthalmic diseases and a screening method for an agent for treating ophthalmic diseases and the like. The present invention also provides a method for predicting rejection associated with transplantation of retinal pigment epithelial cell to patients with ophthalmic diseases.Type: GrantFiled: February 20, 2015Date of Patent: March 26, 2019Assignee: Healios K.K.Inventors: Masayo Takahashi, Sunao Sugita
-
Publication number: 20180258388Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps: (1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.Type: ApplicationFiled: September 8, 2016Publication date: September 13, 2018Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., HEALIOS K.K.Inventors: Satoshi ANDO, Takao KURODA
-
Publication number: 20160244721Abstract: The present invention provides a method of purifying highly pure retinal pigment epithelial cells from a cell population obtained by induction of differentiation of pluripotent stem cells into retinal pigment epithelial cells, by a simple and easy operation in a short period. The purification method of the present invention includes a step of introducing a cell population containing retinal pigment epithelial cells obtained by differentiation induction of pluripotent stem cells on laminin or a fragment thereof on a filter, and obtaining a cell population that passed the filter.Type: ApplicationFiled: October 9, 2014Publication date: August 25, 2016Applicants: HEALIOS K.K., OSAKA UNIVERSITYInventors: Masanori SAWADA, Kiyotoshi SEKIGUCHI
-
Publication number: 20160237403Abstract: Provided are a production method of retinal pigment epithelial (RPE) cells that improves differentiation induction efficiency of pluripotent stem cells into RPE cells, and can provide highly pure RPE cells by a simple and easy operation in a short period, a culture method of RPE cells that can stably grow and culture a cell, a toxicity/efficacy evaluation method using RPE cells useful for transplantation therapy, and a therapeutic drug for a retinal disease. The invention relates to a production method of RPE cells, comprising adhesion culture of human pluripotent stem cells using a culture substrate coated with a laminin-E8 fragment, a culture method of RPE cells, comprising adhesion culture of RPE cells using a culture substrate coated with a laminin-E8 fragment, a toxicity or efficacy evaluation method using RPE cells obtained by producing or culturing by the method, and a therapeutic drug for a retinal disease, containing the RPE cells.Type: ApplicationFiled: October 9, 2014Publication date: August 18, 2016Applicants: HEALIOS K.K., RIKEN, OSAKA UNIVERSITYInventors: Masanori SAWADA, Masayo TAKAHASHI, Kiyotoshi SEKIGUCHI